Eligibility
< 65
All Sexes
What conditions do you have?
Select
Study Summary
This trial studies how well tipifarnib works in treating patients with advanced solid tumors, lymphoma, or histiocytic disorders that have a HRAS gene alteration.
Eligible Conditions
- Rhabdomyosarcoma
- Adrenal Gland Diseases
- Hepatoblastoma
- Glioma
- Recurrent Melanoma
- Recurrent WHO Grade 2 Glioma
- Malignant Solid Neoplasms
- Medulloblastoma
- Refractory Ependymoma
- Histiocytosis
- Recurrent Ectomesenchymoma
- Ependymoma
- recurrent Ewing's Sarcoma
- Kidney
- Recurrent Langerhans Cell Histiocytosis
- Recurrent Malignant Germ Cell Tumor
- Recurrent Malignant Gliomas
- Neuroblastoma
- Lymphoma, Non-Hodgkin
- Osteosarcoma
- Recurrent Peripheral Primitive Neuroectodermal Tumor
- Recurrent Rhabdoid Tumor
- Recurrent Rhabdoid Tumor of the Kidney
- Recurrent Soft Tissue Sarcoma
- Carcinoma
- Refractory Ewing Sarcoma
- Refractory Soft Tissue Sarcomas
- Refractory Thyroid Gland Carcinoma
- Refractory WHO Grade 2 Glioma
- Refractory Adrenal Gland Pheochromocytoma
- Refractory Hepatoblastoma
- Refractory Malignant Germ Cell Tumor
- Refractory Malignant Glioma
- Refractory Osteosarcoma
- Refractory Peripheral Primitive Neuroectodermal Tumor
- Refractory Rhabdoid Tumor
- Refractory Medulloblastoma
- Refractory Melanoma
- Refractory Neuroblastoma
Treatment Effectiveness
Effectiveness Progress
Other trials for Rhabdomyosarcoma
Study Objectives
1 Primary · 2 Secondary · Reporting Duration: Up to 7 years
Year 7
Neoplasms
Year 2
Objective response rate (complete response + partial response) in pediatric patients treated with tipifarnib
Percentage of patients experiencing grade 3 or higher adverse events
Year 7
Progression free survival (PFS)
Up to 7 years
Biomarker analysis
Trial Safety
Safety Progress
This is further along than 68% of similar trials
Other trials for Rhabdomyosarcoma
Side Effects for
Arm B (Clinical Observation)
19%Anemia
17%White blood cell decreased
16%Platelet count decreased
1%Fatigue
Trial Design
1 Treatment Group
Treatment (tipifarnib)
1 of 1
Experimental Treatment
49 Total Participants · 1 Treatment Group
Primary Treatment: Tipifarnib · No Placebo Group · Phase 2
Treatment (tipifarnib)
Drug
Experimental Group · 1 Intervention: Tipifarnib · Intervention Types: DrugTreatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tipifarnib
Not yet FDA approved
Trial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 7 years
Who is running the clinical trial?
National Cancer Institute (NCI)Lead Sponsor
12,990 Previous Clinical Trials
41,297,589 Total Patients Enrolled
86 Trials studying Rhabdomyosarcoma
16,611 Patients Enrolled for Rhabdomyosarcoma
Christine A PratilasPrincipal InvestigatorChildren's Oncology Group
Eligibility Criteria
Age < 65 · All Participants · 10 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:Lesions only detected by nuclear medicine studies (e.g.
Bone marrow infiltration except that detected by MIBG scan for neuroblastoma.
You must have a body surface area > 0.29 m^2 at enrollment.
You have malignant fluid collections (e.g.
Elevated tumor markers in plasma or CSF.
You have previously had radiotherapy for cancer.
The size of the tumor does not meet the measurement requirements for RECIST 1.1.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Who else is applying?
How old are they?
| 18 - 65 | 100.0% |
What site did they apply to?
| Eastern Maine Medical Center | 100.0% |
What portion of applicants met pre-screening criteria?
| Met criteria | 100.0% |
Top Oncology Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments